Brought to you by 
Lycera closes first tranche of $36mm Series A round; adds on
07 Mar 2011
Executive Summary
Lycera (small-molecule immunomodulators) received $10mm of a planned $36mm Series A financing. InterWest Partners, ARCH Venture Partners, and Clarus Ventures co-led (and take seats on Lycera's board), and seed investor EDF Ventures also participated. The remainder of the funds will be available to the company in two additional tranches as specific development milestones are achieved.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lycera closes first tranche of $36mm Series A round; adds on
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice